Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This report documented a case of thrombocytopenia and leukopenia linked to the long-term use of itraconazole in a patient with acute myelogenous leukemia.

This study found that both intralesional pentoxifylline and intralesional corticosteroids improved hair regrowth in patients with localized alopecia areata, but intralesional corticosteroids were more effective, achieving 100% hair regrowth compared to 60% with pentoxifylline.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

In this case study, a 12-year-old girl with severe Crohn colitis achieved impressive clinical and endoscopic remission after receiving infliximab and azathioprine as first-line treatment, suggesting potential benefits of early intensive therapy.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This systematic review investigated colchicine as a potential treatment for various skin conditions, finding that most studies reported generally positive clinical outcomes when used alone or with other drugs, despite some variability in results.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

This review explores the advantages and drawbacks of the anticancer drug paclitaxel, noting its effectiveness in combination with cisplatin for breast cancer survival, its potential for treating non-cancer conditions, and the mechanisms behind its resistance.

This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

This study found that cyclosporine A treatment at 5 mg/kg/day may reduce inflammation and promote gland regeneration in dogs with sebaceous adenitis, though symptoms returned when treatment stopped.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.

This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

Scalp cooling significantly reduces hair loss in chemotherapy patients.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This communication reports previously unreported side effects, severe bullous dermatosis and onycholysis, in three patients undergoing high-dose methotrexate and leucovorin calcium therapy, impacting their chemotherapy schedules.

The authors reported that electrochemotherapy and electroporation-based treatments, both with and without cytotoxic drugs, show promise as safer and more effective options for breast cancer treatment, including metastatic cases and palliative care, in vitro and in vivo.

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

In this report, a patient with vitiligo and systemic lupus erythematosus achieved complete skin repigmentation after 30 days of treatment with the oral JAK inhibitor tofacitinib, with no adverse reactions, suggesting its efficacy and safety as a potential treatment for vitiligo with coexisting autoimmune conditions.